The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Wittenburg
Luke A
LA
Department of Clinical Sciences, James L. Voss Veterinary Teaching Hospital, Colorado State University Animal Cancer Center, Fort Collins, CO 80525, USA. lwittenb@colostate.edu
Bisson
Liam
L
Rose
Barbara J
BJ
Korch
Christopher
C
Thamm
Douglas H
DH
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D002467:Cell Nucleus / Q000378:metabolism; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology*; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology; D013045:Species Specificity; D014635:Valproic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
D000903:Antibiotics, Antineoplastic; D056572:Histone Deacetylase Inhibitors; D014635:Valproic Acid; D004317:Doxorubicin